Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.44 |
| ▸ | PAK4 | O96013 | 2/20 | 0.44 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | WEE1 | P30291 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041687 | 0.81 | JAK3 (0.40) | JAK3AURKACDK1CCNB1CYP3A4 | |
| SCHEMBL15041713 | 0.80 | FGFR1 (0.39) | JAK3PAK4PKN1AURKACDK1 | |
| SCHEMBL15041699 | 0.78 | AURKA (0.43) | JAK3PAK4PKN1JAK2AURKA | |
| SCHEMBL15785307 | 0.78 | PAK4 (0.44) | JAK3PAK4PKN1WEE1TNK2 | |
| SCHEMBL15785220 | 0.78 | PAK4 (0.51) | JAK3PAK4PKN1WEE1PAK1 | |
| SCHEMBL13553830 | 0.78 | PAK4 (0.45) | JAK3PAK4PKN1AURKACDK1 | |
| SCHEMBL15036033 | 0.76 | PAK4 (0.50) | JAK3PAK4PKN1JAK2BRD4 | |
| SCHEMBL15041278 | 0.76 | JAK3 (0.44) | JAK3PAK4PKN1AURKACDK1 | |
| SCHEMBL15041651 | 0.76 | AURKA (0.39) | JAK3PAK4PKN1JAK2BRD4 | |
| SCHEMBL15035128 | 0.75 | PAK4 (0.45) | JAK3PAK4PKN1WEE1TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | JAK3 1901/4885PAK4 5/4885PKN1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.